title: Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics.
abstract: Multiple sclerosis (MS) is a chronic autoimmune disease, where T-cells attack the myelin sheath in the central nervous system (CNS), characterized by relapsing-remitting episodes, or gradually increasing severity of symptoms and disability that accumulate over time. While current MS therapies have been proven in clinical trials to provide significant benefits, they cater only to subsets of patients. Moreover, there is an acute need to identify the most effective and safe treatment appropriate for each patient prospectively, since early intervention has been proven to prevent accumulation of irreversible dysfunction. In this review we discuss the current state-of-the-art in pharmacogenetic research as applied to the common marketed and in-development MS treatments, with respect to both efficacy and safety aspects. We conclude by discussing the relevance of pharmacogenetics and other biomarkers to the prediction, prevention and personalization of MS medications in the horizon.
authors.affiliation: IsraGene, Haifa, Israel  ; Cabernet Pharmaceuticals, R. David Thomas Center, One Science Drive, BOX 90344, Durham, NC 27708 USA.
authors.forename: Iris
authors.initials: I
authors.lastname: Grossman
authors.forename: Ariel
authors.initials: A
authors.lastname: Miller